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Abstract
Ovine GH (oGH) is synthesized in placental tissue during
maximal placental growth and development. Our objectives
were to localize oGH mRNA in the placenta, and study the
impact of exogenous GH on twin pregnancies during the
normal window (35–55 days of gestational age; dGA) of
placental expression. In situ hybridization localized oGH
mRNA in uterine luminal epithelium but not in tissues of
fetal origin. While maternal GH and IGF-I concentrations were
increased (P!0.001) approximately tenfold, uterine, uterine
fluid, placental, and fetal weights were unaffected by treatment at
either 55 or 135 dGA. Fetal length, liver weight, and liver weight
per kg of body weight were unaffected by maternal GH
treatment. However, in the cotyledon, IGF-binding protein
(BP)-1 and IGFBP-4 mRNA concentrations were increased

(P!0.05), while IGFBP-2 mRNA was decreased (P!0.05).
The concentration of mRNA for IGFBP-3 was unaffected by
treatment. Within the caruncle, IGFBP-1 mRNA was
decreased (P!0.05), while IGFBP-3 and IGFBP-4 mRNA
were increased (P!0.05), and IGFBP-2 mRNA was
unchanged due to GH treatment. While our data indicate that
elevated maternal GH and IGF-I concentrations during early
and mid-gestation do not enhance placental and fetal growth in
twin pregnancies, localization of GH mRNA in uterine luminal
epithelium could explain GHs transitory expression from 35 to
55 dGA, since by the end of this period the majority of the
uterine luminal epithelium has fused with chorionic binucleate
cells forming the placental syncytium.

Introduction

(1999) identified oGHR mRNA in the uterine endometrium
from 8 to 120 dGA and identified the primary site of oGHR
mRNA being the trophectoderm at 40 dGA. Collectively,
these data suggest that a functional interaction of oGH and its
receptor may exist during early to mid-gestation within the
sheep uteroplacental unit.
Administration of recombinant porcine GH (rpGH) to
gilts during early to mid-gestation increases fetal and placental
weight (Sterle et al. 1995), and increases in fetal weight and
length have also been reported for underfed gilts given rpGH
during mid-gestation (Gatford et al. 2000). However, studies
in sheep to elucidate the impact of GH administration during
pregnancy have provided variable results. Administration of
GH during conceptus elongation and early placentation has
no effect on placental development (Spencer et al. 1999).
Only endometrial gland proliferation was stimulated and this
effect was seen with concurrent interferon-t administration
(Spencer et al. 1999). Wallace et al. (2004) reported an increase
in uteroplacental weight due to GH infusion from 35–80
dGA; however, this is due likely to increased fetal fluid weight
resulting from polyhydraminios, as total and average
placentome weights and fetal weights were not statistically

Sheep have two growth hormone (GH) genes (ovine GH-1
(oGH-1) and oGH-2), and oGH-2 has multiple alleles (oGH2N and oGH-2Z; Valinsky et al. 1990, Gootwine et al. 1993).
Expression of the oGH-2 gene has been detected in sheep
placenta (Lacroix et al. 1996, 1999) and it was inferred that
both the N- and Z-alleles of the gene are expressed (Ofir &
Gootwine 1997). oGH mRNA and protein have been
detected in the placenta during early to mid-gestation
(Lacroix et al. 1996, 1999), with the predominant window
of oGH expression occurring between 35 and 55 days of
gestational age (dGA). Immunolocalization of oGH within
maternal syncytial and stromal cells, as well as the fetal
trophoblast, has been reported for 40–45 dGA placentomes
(Lacroix et al. 1996). This group also reported in situ
hybridization of oGH mRNA in the syncytium and
trophoblast layers of the placenta at 40 dGA (Lacroix et al.
1999). The oGH receptor (oGHR) mRNA was initially
identified in the placenta at 51, 95, and 120 dGA (Klempt
et al. 1993) and was localized to what was identified as uterine
epithelium and uterine glands at 120 dGA. Lacroix et al.
Journal of Endocrinology (2008) 198, 91–99
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different as a result of GH treatment. Furthermore, the
increase in uteroplacental weight (Wallace et al. 2004) was
only seen in adolescent ewes maintained on a high dietary
intake, a feeding regimen used in adolescent ewes to generate
fetal growth restriction (Wallace et al. 1997, Anthony et al.
2003). More recently, treatment of ewes from 35–65 dGA
with GH failed to alter fetal or placental development
(Wallace et al. 2006), as measured some 65 days later, and the
GH was only administered to the high intake adolescent ewes.
Interestingly, in over-nourished adolescent ewes, serum GH is
decreased while serum insulin-like growth factor-I (IGF-I) is
increased (Wallace et al. 1997), indicating a disconnect of the
normal endocrine relationship between GH and IGF-I.
Administration of GH during mid-pregnancy (70–83
dGA) in normal sheep pregnancies results in increased
maternal serum non-esterified fatty acids, IGF-I and glucose,
but no change in fetal growth (Jenkinson et al. 1999). Fetal
weight was also increased 10% by GH infusion at 98–111
dGA (Jenkinson et al. 1999); however, several reports saw no
effect on fetal or placental weight with similar temporal
administration of GH (Stelwagen et al. 1994, Currie et al.
1996, Harding et al. 1997). Interestingly, all of the studies
discussed above did not administer exogenous GH concurrent
with placental GH expression (w35–55 dGA) within the
placenta (Lacroix et al. 1996, 1999). It remains to be seen what
the effects of GH administration, concurrent with the normal
placental expression window, will have in sheep. Therefore, it
was our objective to further define the location of oGH
expression in the placenta and to determine the effects of
exogenous recombinant bovine GH (rbGH) administration
during the normal window of placental oGH expression in
twin sheep pregnancies. We chose to study twin pregnancies,
as multiple fetuses place increased demand on the maternal
system and placenta to provide adequate nutrition to the fetus.

Materials and Methods
cDNA generation
In order to verify the origin of oGH expression within the
placenta of sheep, placentomes were collected from 45 dGA
pregnancies following killing according to Colorado State
Univeristy IACUC approved protocol 02-304A. Intact

placentomes were excised, trimmed to 5 mm cross-sections,
and fixed overnight in 4% paraformaldehyde, before being
embedded in paraffin. cDNA for oGH, vimentin (marker of
fibroblast cell lineage), cytokeratin 18 (marker of epithelial
cell lineage), and CD 18 (marker of leukocytes) were
generated by RT PCR. The cDNA used for in situ
hybridization of ovine placental lactogen (oPL) has previously
been reported (Kappes et al. 1992). For the reverse
transcriptase reaction, the SuperScript First Strand Synthesis
kit (Invitrogen) was used following the manufacturer’s
protocol. The PCR products were generated by 40 cycles
of 95 8C 1 min to denature, 1 min to anneal (8C in Table 1),
and 72 8C 1 min for extension. The PCR amplicons were
inserted into PCR-Script Amp SK (Stratagene, Cedar Creek,
TX, USA) for transformation, sequence validation, and
subsequent propagation. Plasmid DNA was harvested by
alkaline lysis, and purification by centrifugation through a
CsCl gradient (Liang et al. 1999, Limesand & Anthony 2001).
The plasmid preparations were sequenced by Macromolecular Resources (Colorado State University) to verify
sequence authenticity.

In situ hybridization
To generate template for in situ hybridization, oGH (406 bp;
EcoRI), oPL (533 bp; BamHI and NdeI), oVimentin (369 bp;
EcoRI and NotI), oCytokeratin 18 (1307 bp; XhoI), and oCD
18 (679 bp; EcoRI and SacI) were digested from their
respective plasmids and gel purified on 1% agarose gels. For
a negative control, w400 bp of non-coding sequence from
PCR-Script Amp were digested out of intact plasmid with
NspI and SacII. Radiolabeling of cDNA for in situ hybridization was performed using a 50–100 ng template with the
DECAprime II random prime labeling kit (Ambion, Austin,
TX, USA) and radiolabeled cytosine tri-phosphate (33PadCTP) per the manufacturer’s instructions. Only probes with
specific activities exceeding 5!108 c.p.m./mg DNA were
used for in situ analysis. In situ hybridization was performed as
described previously (Kappes et al. 1992).

Exogenous GH administration
Twenty-three whiteface crossbred ewes were naturally mated
to a single sire, generating twin pregnancies. All procedures

Table 1 PCR primers, annealing temperatures, and product sizes for cDNA used in real-time PCR analysis

cDNA
IGF-I
IGF-II
IGFBP-1
IGFBP-2
IGFBP-3
IGFBP-4
RPS15

Forward primer

Reverse primer

Anneal (8C)

Product (bp)

tcgcatctctcttctatctggccctgt
gaccgcggcttctacttcag
tgatgaccgagtccagtgag
caatggcgaggagcactctg
ctcagagcacagacaccca
tgtgcgtgtgtgttgatg
atcattctgcccgagatggtg

acagtacatctccagcctcctcaga
aagaacttgcccacggggtat
gtccagcgaagtctcacac
tggggatgtgtagggaatag
ggcatatttgagctccac
gagggagccaagatgagt
tgctttacgggcttgtaggtg

62
62
62
55
54
62
60

238
202
248
330
335
229
134
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were approved under Colorado State University IACUC
protocol 02-304A. At 35 dGA, the ewes were assigned to
treatment groups for s.c. injections of GH (GH, nZ10) or
buffer control (CON, nZ13). The GH group received
0.2 mg/kg body weight (BW) of rbGH (Monsanto, St Louis,
MO, USA) per day reconstituted in 100 mM NH4HCO3
buffer. The rbGH was administered by twice daily injections
of 3 ml 12 h apart. The CON group received two injections
of 3 ml of 100 mM NH4HCO3 buffer. The injection regimen
lasted for 20 days (35–55 dGA) to coincide with the normal
expression window of oGH within the placenta (Lacroix
et al. 1996, 1999). Prior to, and every 5 days during rbGH
administration, blood samples were collected by jugular
venipuncture to compare serum hormone concentrations of
CON and GH groups.
Between 54–56 dGA, 7 CON, and 5 GH ewes were killed
(90 mg/kg sodium pentobarbitol) and uterine, placental, and
fetal tissues were collected for analysis. Ewe weight, gravid
uterine weight, placental weight, and fetal parameters (sex,
weight, crown rump length (CRL), and liver weight) were all
recorded. The seven CON pregnancies yielded nine male and
five female fetuses, whereas the five GH pregnancies yielded
five male and five female fetuses. Using CRL and fetal weight,
the ponderal index (PI) for each fetus was calculated (PIZ
weight in grams/length in cm3). Cotyledon and caruncle
tissue from each placenta were manually separated and
snap frozen in liquid nitrogen for RNA analysis later. The
remaining ewes (CON, nZ6; GH, nZ5) were gestated until
135 dGA to evaluate the effects of early gestation rbGH
administration near term. Ewes were killed between 133 and
138 dGA, and the same data and tissue samples were collected
as the 55 dGA groups. The 6 CON pregnancies yielded
2 male and 10 female fetuses, whereas the 5 GH pregnancies
yielded 4 male and 6 female fetuses. Additionally, empty
uterine weight was measured for use in calculating fluid
weight within the uterus. To calculate fluid weight, fetal,
placental, and empty uterine weights were subtracted from
gravid uterine weight.

Serum hormone analyses
A validated GH RIA was used to determine serum GH levels
(Hoefler & Hallford 1987) for duplicate samples. Using
NIDDK anti-oGH and NIDDK oGH, the intra-assay
coefficient of variation was 7.2% and recovery was 97% for
15 ng. A two-site IRMA (Diagnostic Systems Laboratories,
Webster, TX, USA) was used to assay serum IGF-I as directed
by the manufacturer. Intra- and interassay coefficients of
variation were 3.43 and 3.39% for the 50 ng/ml control
respectively, and 2.29 and 2.27% for the 200 ng/ml control.

Northern hybridization analysis
Radiolabeling of cDNA for northern hybridization was
performed using 50–100 ng template in the DECAprime II
random prime labeling kit (Ambion) and using 32Pa-dCTP
www.endocrinology-journals.org
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per the manufacturer’s instructions. Only cDNAs with
specific activities exceeding 5!108 c.p.m./mg DNA were
used for analysis. Caruncle total cellular RNA (tcRNA)
was hybridized with oGH cDNA, while cotyledon tissue was
hybridized with oPL cDNA as described previously (Kappes
et al. 1992). The membranes were exposed to a Phosphor
Screen (Molecular Dynamics, Sunnyvale, CA, USA) overnight for oPL and 48 h for oGH. The screens were scanned
using a Storm Imager (Molecular Dynamics) to visualize
hybridization. The membranes were then stripped with
repeated washes of 200 ml boiling stripping buffer (0.05!
SSC, 10 mM EDTA and 0.1% SDS), blocked with prehybridization buffer, and hybridized with ribosomal protein
S15 (RPS15) cDNA (2!106 c.p.m./ml) to serve as a
normalization control. For northern hybridization analysis,
the expression of RPS15 (Rozance et al. 2007) was used for
normalization. The concentration of RPS15 was used for
normalization due to changes by treatment in other housekeeping genes tested (actin and glyceraldehydes-3-phosphate
dehydrogenase). Following hybridization, the membranes
were exposed to a Phosphor screen overnight and scanned
with the Storm Imager. Densitometric analysis of the Storm
images for all northern hybridizations was completed with
ImageQuant 5.0 (Molecular Dynamics).

Quantitative reverse transcriptase PCR
tcRNA was isolated as described previously (Warren et al.
1990, Kappes et al. 1992). An aliquot of the stock tcRNA
samples was diluted to a concentration of 1 mg/mlG0.2 mg/ml
for use as a working solution. The concentration of the
working solutions was verified using the Ribogreen
(Molecular Probes, Eugene, OR, USA) RNA quantification
system. Measurements of fluorescence were taken using a
Mithras LB 940 (Bertold Technologies, Oak Ridge, TN,
USA). The samples were excited at 485 nm and emission was
measured at 535 nm. The counting time was 0.1 s and the
lamp energy was set at 10 000. The unknowns were
compared against an RNA standard curve.
For the reverse transcriptase reaction, 2 mg tcRNA was
used in the SuperScript First Strand Synthesis kit (Invitrogen).
All samples of tcRNA for both caruncle and cotyledon were
incubated at the same time with the same kit to avoid sample
variation due to technician and/or kit variation. The yield of
cDNA from the RT reactions was quantified with the
Oligreen (Molecular Probes) ssDNA quantification kit.
Samples were excited and measured with the Mithras LB
940 with the same settings as for the Ribogreen analysis.
Following quantification, all samples were set to a cDNA
concentration of 12.5 ng/ml to be used in quantitative PCR
(qPCR). The qPCR mix was 12.5 ml iQ SYBR Green
Supermix (Bio-Rad), 200 nM primer (forward and reverse),
2 ml cDNA (25 ng), and balanced to 25 ml total volume with
sterile water with a neutral pH. For all qPCRs, the first
denaturing step was 95 8C for 5 min and 45 s thereafter, the
annealing time was 1 min with gene-specific temperature
Journal of Endocrinology (2008) 198, 91–99
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(Table 1), and 1 min of extension at 72 8C. The reactions
were run for 40 cycles, with a fluorescence measurement after
each cycle, followed by a melting curve analysis initiated at
55 8C and measuring fluorescence every 0.5 8C to 95 8C. For
the qPCR analysis, cDNA for ovine IGF-I, IGF-II, and IGFbinding proteins (BP) 1, 2, 3, and 4 (de Vrijer et al. 2006) and
RPS15 (Rozance et al. 2007) were used as standard templates.
The standard curve template concentrations spanned 100 to
1!10K5 pg/ml at tenfold increments. For each standard, 1 ml
template was supplied to the reaction mix with the same
primer concentration. Table 1 lists the primer sequences,
annealing temperatures, and product sizes generated by PCR.
Primers were designed to span at least one intron of the
mRNA sequence for each gene of interest and produce
130–350 bp of product. For each gene of interest, the qPCRs
were optimized as described previously (Erickson-Hagen
et al. 2005) to obtain apmplification efficiencies of 90–100%,
and were validated by electrophoresis of the PCR products to
verify correct product size prior to analysis. The standard
reactions were run in duplicate and the unknown reactions
were run in triplicate. The means are presented as gene of
interest cycle threshold divided by RPS15 cycle threshold
(Ct/Ct).

Statistical analysis
For the maternal and fetal data collected at necropsy, two-way
ANOVA (treatment and fetal sex as dependent variables) was
conducted on the data obtained at 55 (7 CON and 5 GH twin
preganancies) and 135 (6 CON and 5 GH twin pregnancies)
dGA separately. Since there were no significant sex effects or
treatment–sex interactions, fetal sex was removed from the
statistical model, making student’s t-test appropriate for
comparing treatment effects (CON versus GH), at each
gestational age (55 or 135 dGA). Serum hormone data means
(CON and GH) for each sample day also were separated by
student’s t-test, as were normalized means for northern and
qPCR analyses for the CON and GH.

Results
Localization of oGH mRNA
In situ hybridization analysis of placentome sections revealed a
distinct population of cells at the maternal–fetal interface that
hybridized with the oGH cDNA (Fig. 1A and B). oGH
hybridization did not appear to reside within the fetal
trophoblast layer, which contain chorionic binucleate cells
(BNCs) as identified by oPL hybridization (Fig. 1C and D).
To determine what cell-type expresses oGH, oCytokeratin
18, and oVimentin radiolabeled cDNAs were hybridized to
day 45 placentome sections as well. Figure 1E–H represent
light and dark phase images of oCytokeratin 18 and
oVimentin hybridization respectively. Ovine cytokeratin 18
hybridized to the maternal epithelium (Fig. 1E and F),
Journal of Endocrinology (2008) 198, 91–99

Figure 1 (A and B) In situ hybridization with oGH cDNA. (A) A light
field image of day 45 placentome. (B) The dark field of the same
location. Positive hybridization is detected in UE. (C and D) In situ
hybridization with oPL cDNA. (C) A light field image of day 45
placentome. (D) The dark field of the same location. Positive
hybridization detected in FT binucleate cells. (E and F) In situ
hybridization with cytokeratin 18 cDNA. (E) A light field image of
day 45 placentome. (F) The dark field of the same location. Positive
hybridization is detected in UE. (G and H) In situ hybridization with
vimentin cDNA. (G) A light field image of day 45 placentome.
(H) The dark field of the same location. Positive vimentin
hybridization is detected in MVS. FT, fetal trophoblast; FVS, fetal
villous stroma; MVS, maternal villous stroma; UE, uterine
epithelium; final magnificationZ400!.

whereas vimentin hybridization was apparent in the maternal
villous stroma and to a lesser extent in the fetal villous stroma
(Fig. 1G and H). The pattern of hybridization for oGH and
oCytokeratin 18 was similarly located at the maternal–fetal
interface, and was not consistenly present throughout the
boundary of the maternal tissue (Fig. 1A and E). The oGHpositive cells were in random clusters at outer boundaries of
maternal tissue, not in the maternal stroma or fetal
trophoblast, and appear to be the remnants of the maternal
uterine epithelium. To verify that these cells were not of
leukocyte origin, sections were hybridized with our oCD18
cDNA. The CD18-positive cells were deep in the
endometrium and myometrium, far from the oGH-positive
cells within the maternal epithelium (data not shown).
www.endocrinology-journals.org
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Effect of rbGH administration on maternal and fetal characteristics
Exogenous rbGH was administered twice daily to pregnant
ewes from days 35 to 55 of gestation, resulting in greater
(P!0.001) concentrations of serum GH by day 5 of
treatment (Fig. 2), which remained approximately tenfold
higher than the controls throughout the treatment period.
The exogenous rbGH was biologically active in sheep as the
treated ewes exhibited increases (P!0.001) in serum IGF-I
concentrations, as evidenced in Fig. 2.
The physical data, for the ewes, fetuses and placenta
collected at necropsy are summarized in Tables 2 and 3. For
the 55 dGA groups, no differences were seen in uterine
weight, placental weight, fetal weight, CRL, PI, liver weight,
or liver weight expressed per kg of BW between GH and
CON pregnancies. Similar results were obtained in the near
term (135 dGA) ewes. No significant differences were seen
between uterine, placental, calculated fluid, and fetal weights.
Additionally, no significant differences were found in CRL,
PI, liver weight, or liver weight/kg BW between treatments
in the 135 dGA groups. There was no effect of fetal sex on the
fetal parameters measured at days 55 and 135.

Effect of rbGH administration on placental gene expression
To assess placental tissue response to exogenous GH,
cotyledon and caruncle tissues were collected from each 55
dGA pregnancy, and northern hybridization analysis was used
to detect changes in cotyledon and caruncle concentrations of
oPL and oGH mRNA (Fig. 3). Robust signal was obtained

C D WRIGHT and
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Table 2 Day 55 maternal and fetal physical data. Data for control
(CON) and GH treated (GH) ewes are presented as meanGS.E.M.

Treatment
Pregnancies (n)
Days post coitus
Ewe weight (kg)
Gravid uterine
weight (g)
Placental weight (g)
Fetal weight (g)
Crown rump
length (cm)
Ponderal index
(g/cm3)
Liver weight (g)
Liver weight/kg BW

CON

GH

P value

7
55.14G0.26
85.29G2.31
1773.57G73.72

5
55G0.32
82.82G5.38
1934G59.32

0.734
0.610
0.336

693.26G59.58
32.23G1.18
8.26G0.16

709.06G90.75
32.03G1.28
8.48G0.15

0.882
0.910
0.346

0.057G0.002

0.053G0.001

0.075

2.64G0.15
81.62G2.09

2.48G0.11
77.56G1.98

0.426
0.190

for oGH in maternal caruncles, and for oPL in the fetal
cotyledons, further supporting that oGH mRNA resides in
the maternal placental component. However, there was no
effect of GH treatment on cotyledon oPL mRNA concentrations or maternal caruncle oGH mRNA concentrations
(Fig. 3).
Cotyledon mRNA concentration for IGF-I, IGF-II, or
IGFBP-3 was not impacted by GH treatment (Fig. 4).
However, the concentration of mRNA encoding IGFBP-1
and -4 was increased (P!0.05), while IGFBP-2 mRNA
concentration was decreased (P!0.05) in the GH-treated
fetal placenta. Figure 5 presents the comparison of relative
expression of the transcripts within the caruncle. No
significant differences were detected between treatments for
caruncle IGF-I, IGF-II, and IGFBP-2 mRNA concentrations. The concentration of caruncular IGFBP-1 mRNA

Table 3 Day 135 maternal and fetal physical data. Data for control
(CON) and GH treated (GH) ewes are presented as meanGS.E.M.

Figure 2 Serum GH and IGF-I concentrations. Concentrations for
control (CON) and GH-treated (GH) ewes throughout the gestation
treatment period (days 35–55) are presented as meanGS.E.M. with
significant differences marked with an asterisk.
www.endocrinology-journals.org

Treatment
Pregnancies (n)
Days post coitus
Ewe weight (kg)
Gravid uterine
weight (kg)
Placental weight (kg)
Fluid weight (kg)
Fetal weight (kg)
Crown rump
length (cm)
Ponderal index
(g/cm3)
Liver weight (g)
Liver weight/kg BW

CON

GH

P value

6
136.00G0.97
91.29G4.78
13.80G0.81

5
136.20G0.80
97.27G5.36
14.06G0.66

0.880
0.425
0.816

1.45G0.09
2.26G0.39
4.45G0.17
50.36G0.79

1.50G0.11
2.21G0.21
4.54G0.13
51.70G0.82

0.748
0.915
0.655
0.332

0.035G0.001

0.033G0.001

0.325

117.43G6.36
26.33G0.77

125.20G8.39
27.40G1.31

0.462
0.473
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Figure 5 Relative expression of IGF-I, IGF-II, IGFBP-1, -2, -3, and -4
mRNA in caruncle tissue. All transcripts were corrected (Ct/Ct) with
RPS 15 mRNA. Data are expressed as meanGS.E.M. and significant
differences (P!0.05) are indicated by an asterisk.

Figure 3 Relative expression of oPL in the fetal cotyledon and oGH
in the maternal caruncle at 55 dGA. Densitometric values for the
samples were normalized by densitometric values for RPS 15. Ten
micrograms tcRNA were loaded for northern hybridization.

was significantly (P!0.05) decreased, while the concentrations of IGFBP-3 and -4 mRNA were both significantly
(P!0.05) increased by GH treatment.

Discussion
GH has been previously detected in the ovine placenta from days
35 to 55 of gestation; however, the cellular source of
GH described (Lacroix et al. 1996, 1999) did not coincide
with our preliminary studies (TRH Regnault & RV Anthony
unpublished observations). Therefore, the first objective of this

Figure 4 Relative expression of IGF-I, IGF-I, IGFBP-1, -2, -3, and -4
mRNA in cotyledon tissue. All transcripts were corrected (Ct/Ct) by
RPS 15 mRNA. Data are expressed as meanGS.E.M. and significant
differences (P!0.05) are indicated by an asterisk.
Journal of Endocrinology (2008) 198, 91–99

research was to definitively localize the expression of oGH in day
45 placentome tissue. The results of our in situ hybridization
contrast with those reported by Lacroix et al. who reportedly
detected oGH in maternal syncytium and stromal cells, and fetal
trophoblast. The use of in situ hybridization and visualization at
high magnification reported here specifically detected hybridization of oGH at the maternal–fetal interface (Fig. 1A and B).
These cells were not chorionic BNC derived, as marked by oPL
(Fig. 1C and D). The cells that hybridized to the oGH cDNA
also showed positive hybridization for cytokeratin 18 (Fig. 1E
and F) a marker of epithelial cells and not vimentin, a marker of
fibroblast-derived cells. Additionally, the oGH-positive cells
were negative for CD 18 hybridization precluding them from
being leukocyte in origin (data not shown).
The results of the in situ hybridization analysis indicate that
oGH is expressed in maternal uterine epithelium and is not
detected in maternal villous stroma nor fetal trophoblast or
villous stroma. Our detection of oGH in day 45 placental
tissue coincides with the reported maximal expression of
oGH (Lacroix et al. 1999). The pattern of oGH expression
beginning at day 35, peaking at day 45, and decreasing to day
55 reported by Lacroix et al. is further supported by a much
less robust detection of oGH in day 55 placentomes (TRH
Regnault & RV Anthony unpublished observations). While
we do not understand the initiation of oGH in the placenta at
w35 dGA, the mechanism by which oGH expression is
terminated may be the loss of the cells producing oGH. The
loss of maternal epithelium within the caruncle due to
syncytium formation is well documented, and by 55–60 dGA
the epithelium is not detectable (Davies & Wimsatt 1966,
Stegeman 1974). Therefore, the cessation of oGH expression
is likely not a change in transcriptional regulation, but the loss
of oGH producing cells.
Maternal GH infusion late in gestation (days 98–111) has
been shown to increase fetal growth in singleton pregnancies
( Jenkinson et al. 1999); however, these results are not
consistent within the same breed receiving the same oGH
treatment (Currie et al. 1996). Wallace et al. initiated GH
administration to adolescent ewes at the appropriate time (day
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35); however, the GH treatment continued to day 80 (Wallace
et al. 2004), well past the reported cessation of oGH
expression in the placenta (Lacroix et al. 1996, 1999).
Although Wallace et al. reported an increase in placental
weight in the over-nourished adolescent ewes with singletons; these ewes are predisposed to placental and fetal growth
restriction due to the high plane of nutrition. The overnourished adolescent ewes exhibit an interesting change in
GH/IGF-I endocrinology. These ewes have decreased
maternal serum GH while at the same time have increased
serum IGF-I (Wallace et al. 1997). This indicates a
disconnection of the normal positive endocrinology of GH
and IGF-I. Therefore, caution should be used when
interpreting the results of maternal oGH infusion in this
model. Maternal infusion of GH maternally may have
resulted in increases in placental weight; however, this may
represent a resetting of the normal GH/IGF-I system thus
providing a repartitioning of nutrients toward the pregnancy
to normalize placental and fetal growth.
In our research, maternal GH treatment increased
(P!0.001) maternal serum concentrations of GH and IGF-I
tenfold higher than CON ewes, by the fifth day of treatment,
and maintained the increase throughout treatment. The peak
GH concentration was similar to that reported by Jenkinson
et al. (1999) while the peak IGF-I concentration was similar to
Stelwagen et al. (1994) and Jenkinson et al. (1999). Although
the ewes responded to GH treatment with increased maternal
serum IGF-I, exogenous GH treatment had no effect on
uterine, placental, and fetal weight or fetal organ weights
measured at either day 55 or 135 of gestation. While the model
systems are different, our results none the less agree with the
recent reports of GH administration during early gestation
(Wallace et al. 2006). The study by Wallace et al. (2006) did not
administer GH to the moderate intake control fed adolescent
ewes, and the GH-treated high intake adolescent ewes
carrying singletons, confounding the comparison between
their study and ours. However, taken together, these results
support the conclusion that elevated maternal serum GH and
IGF-I concentrations during the normal expression window of
oGH have little impact on placental and fetal growth. We
specifically chose twin pregnancies to evaluate, as the multiple
fetuses put increased demand on the maternal system and
placenta to provide sufficient nutrition to the fetus. The only
report of GH administration to ewes carrying twins was that of
Jenkinson et al. (1999), in which ewes were treated from 98 to
111 dGA. A significant increase in fetal weight was reported
( Jenkinson et al. 1999), but GH treatment had similar effects on
the growth of both singles and twins. The response seen by
Jenkinson et al. may well be due to partitioning of maternal
nutrients toward the pregnancy late in gestation versus an
alteration of placental development.
In an effort to gain insight into the potential effects of GH
on gene expression within the placenta, we used northern
hybridization and qPCR to quantify GH, oPL, IGF-I,
IGF-II, and IGFBP-1, -2, -3, and -4 mRNA concentrations
in day 55 caruncle and cotyledon tissue. Maternal GH
www.endocrinology-journals.org
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treatment had no effect on GH expression in the caruncle
tissue, nor did GH impact oPL expression in cotyledon tissue.
In placental growth, IGF-II plays a crucial role as evidenced
by growth restriction in knockout and targeted disruption
studies (DeChiara et al. 1990, Constancia et al. 2002). Had the
exogenous GH significantly changed the IGF-II levels in the
placenta, it would be expected that a change in placental
growth would be evident. The role of IGF-I may be as a less
potent stimulator of proliferation that has stimulatory effects
on trophoblast differentiation and migration (Maruo et al.
1995, Lacey et al. 2002). With no gross changes in placental
weight and fetal weight evident at necropsy, the lack of effect
on IGF mRNA concentrations is not surprising.
By contrast, within the cotyledon, maternal GH treatment
increased expression of IGFBP-1 and -4, while IGFBP-2
expression was decreased and IGFBP-3 was unchanged.
Within the caruncle exogenous GH increased expression of
IGFBP-3 and -4, while decreasing the expression of IGFBP1. In the caruncle, IGFBP-2 was unaffected by maternal GH
treatment. Previously, it was believed that IGFBP-1 was not
expressed beyond 21 dGA (Wathes et al. 1998, de Vrijer et al.
2006); however, here we could detect changes in IGFBP-1 by
treatment at 55 dGA. We do not discount the previous results,
as our detection of IGFBP-1 is most likely due to the
increased sensitivity of qPCR versus hybridization technologies in detecting transcripts. The decrease in caruncle
expression of IGFBP-1 can be attributed to two possible
mechanisms. First, IGFBP-1 is inversely regulated by insulin
(Suikkari et al. 1989), and it has been shown previously that
GH administration during gestation leads to hyperinsulinemia
(Wallace et al. 2004). Given that we achieved significant
stimulation of IGF-I similar to that reported by Wallace et al.
one could reason that we generated a similar insulin response
that reduced caruncle expression of IGFBP-1. Second, it has
been shown that IGF-II can regulate IGFBP-1 expression at
the maternal interface to control trophoblast invasion
(Hamilton et al. 1998, Irwin et al. 2001). Although we did
not measure maternal serum IGF-II concentrations, an
increase of serum IGF-II due to GH treatment could also
reduce the IGFBP-1 expression in the caruncle. The increase
in caruncular IGFBP-3 agrees with reports that both GH and
IGF-I are stimulatory to IGFBP-3 expression as reviewed by
Clemmons (1997). The increased expression of IGFBP-4 is
not surprising, as it has been reported to be a negative
regulator of IGF-I action in other tissues (Clemmons 1997).
Within the caruncle, IGFBP-4 may be upregulated to
mitigate the effects of increased serum IGF-I.
Within the cotyledon, it is more difficult to interpret the
changes in IGFBP-1, -2, and -4. Given the low amount of blood
in a day 55 fetus, it is not feasible to obtain serum analysis of GH,
IGF-I, IGF-II, and insulin in fetal circulation. These hormones,
as discussed above, regulate the expression of IGFBPs and thus
determination of their concentration would be necessary to give
accurate interpretation of the transcriptional changes within the
placenta. This is the first evidence of the transcriptional changes
caused by GH administration during the normal placental oGH
Journal of Endocrinology (2008) 198, 91–99
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expression window within the placenta. While we did not alter
the local expression of oGH in the placenta, this may be
indicative of alternative regulation of oGH in the placenta versus
the pituitary. Our evidence suggests that increased serum GH
does not cause the normal negative feedback on GH expression
in the placenta that is seen in the pituitary. Cloning and analysis
of the complete promoter sequence for oGH-1 and oGH-2 may
lead to discovery of differential regulation of the promoters.
Heterologous studies with the human GH genes revealed that
hGH-V lacked a proximal pituitary-specific protein (Pit-1) site
that is one of two present in the hGH-N promoter (Nickel et al.
1991). Furthermore, we could not detect expression of Pit-1 in
maternal- or fetal-derived placental tissues (data not presented).
This indicates a tissue-specific transcriptional regulation for
human GH in the placenta when compared with the pituitary.
With the lack of placental response to maternal GH treatment,
further research to elucidate the role of placental oGH will likely
necessitate a knockdown of oGH expression to gain insight into
oGH function within the placenta.
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